Insiders Are Aggressively Buying These Down, But Not Out, Stocks

As we’ll continue to tell you, any time an insider buys their own stocks, tag along.

After all, it’s the insiders – the CEOs, COOs, board members, etc. – who know their company inside and out. And if they’re buying, there’s often a good reason for it.

That being said, here are two stocks seeing healthy, recent insider buying.

Dollar Tree (SYM: DLTR)

Over the last few days, shares of Dollar Tree dropped from about $115 to $94.48 on earnings.

In its most recent quarter, the company did manage to beat expectations. However, the stock did slip after DLTR issued a soft forecast for third quarter adjusted earnings. Following that news, CFO Stewart Glendinning bought 500 shares for $99.50. A few days later, he made an additional purchase of 3,000 shares at prices ranging from $97.00 to $97.87.

Helping, analysts at Morgan Stanley just raised their price target on DLTR to $105 from $96.

“The firm noted that Dollar Tree’s top-line trends are solid and can continue into the second half of 2025, suggesting confidence in the discount retailer’s revenue performance,” as noted by Investing.com.

Cassava Sciences (SYM: SAVA)

Beaten down shares of Cassava Sciences are showing signs of life on news its President and CEO just bought 237,941 shares for about $534,743. Those shares were bought between September 18 and 19, with prices ranging from $2.13 to $2.29.

While the stock plummeted on company plans to stop its Alzheimer drug studies late last year, it appears most of the negativity has been priced in. Seeing the company’s President and CEO putting his money where his mouth is, creates optimism for the down, but not out stock.

According to the President and CEO, “We have initiated a new program focused on TSC-related epilepsy, a rare disease for which patients urgently need more treatment options. Two encouraging animal model studies—one conducted at Yale and another with the TSC Alliance—support the exploration of simufilam as a novel, first-in-class approach to this disease.”

Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsy, added the company in a recent press release.

Featured Pick: A Potential $20 → $300+ Opportunity by 2035

Based on my analysis, this under-$20 stock could potentially reach $300 per share as the quantum computing revolution unfolds in the coming years.

That's a potential 1,500% gain by 2035 from what could be the most important technological shift since the internet.

But opportunities like this don't last forever.

Once Wall Street discovers this story, the chance to buy under $20 could disappear overnight.

See the potential 15X opportunity here.